HC Wainwright & Co. Reiterates Buy on Protagonist Therapeutics, Maintains $38 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Douglas Tsao has reiterated a 'Buy' rating on Protagonist Therapeutics (NASDAQ:PTGX) and maintained a price target of $38.
August 04, 2023 | 3:18 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics has received a reiterated 'Buy' rating from HC Wainwright & Co. with a maintained price target of $38.
The reiterated 'Buy' rating and maintained price target by HC Wainwright & Co. indicates a positive outlook for Protagonist Therapeutics. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100